SCHEMBL3528456

SCHEMBL3528456

CN(C)/C=N/S(=O)(=O)c1ccc(Br)c(F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.55
GAA P10253 1/20 0.55
IDO1 P14902 1/20 0.36
ALDH1A1 P00352 3/20 0.35
POLB P06746 1/20 0.35
NPC1 O15118 1/20 0.35
ALOX12 P18054 1/20 0.35
RAB9A P51151 1/20 0.35
MAPT P10636 2/20 0.35
CA1 P00915 7/20 0.35
CA2 P00918 7/20 0.35
CA9 Q16790 6/20 0.35
CA12 O43570 3/20 0.35
GPBAR1 Q8TDU6 1/20 0.34
CA7 P43166 2/20 0.33
CA4 P22748 1/20 0.33
CA6 P23280 1/20 0.33
CA5A P35218 1/20 0.33
CA14 Q9ULX7 1/20 0.33
CA5B Q9Y2D0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3528460 1.00 LMNA (0.55) LMNAGAAIDO1ALDH1A1POLB
SCHEMBL30307815 1.00 LMNA (0.55) LMNAGAAIDO1ALDH1A1POLB
SCHEMBL20502315 1.00 LMNA (0.55) LMNAGAAIDO1ALDH1A1POLB
SCHEMBL20502320 0.86 LMNA (0.60) LMNAGAAALDH1A1POLBGPBAR1
SCHEMBL10529809 0.86 LMNA (0.60) LMNAGAAALDH1A1POLBGPBAR1
SCHEMBL10529805 0.86 LMNA (0.60) LMNAGAAALDH1A1POLBGPBAR1
SCHEMBL13099867 0.81 LMNA (0.54) LMNAGAAALDH1A1POLBGPBAR1
SCHEMBL3101846 0.81 LMNA (0.54) LMNAGAAALDH1A1POLBGPBAR1
SCHEMBL3101841 0.81 LMNA (0.54) LMNAGAAALDH1A1POLBGPBAR1
SCHEMBL7617768 0.80 LMNA (0.61) LMNAGAAALDH1A1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7759366-B2 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use SANOFI-AVENTIS (FR) 2010-07-20 US disclosed
US-20090215728-A1 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use SANOFI-AVENTIS (FR) 2009-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215728-A1 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use GPR119, GIPR, LIPC LMNA 815/4885GAA 157/4885IDO1 574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.